Amifostine in the management of radiation-induced and chemo-induced mucositis

4 April 2006

journal article
review article
Published by Springer Nature in Supportive Care in Cancer

Vol. 14 (6) , 566-572
https://doi.org/10.1007/s00520-006-0047-4

Abstract

Mucositis is a significant complication of cancer therapy, with important clinical and economic implications. In June 2005, the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) conducted an evidence-based update review of the literature on mucositis. The goal of this literature review is to update previously published guidelines for the management of mucositis. This article reports the findings of the subgroup charged with reviewing the literature related to amifostine.

Keywords

AMIFOSTINE . MUCOSITIS . RADIOTHERAPHY . CHEMOTHERAPHY

This publication has 43 references indexed in Scilit:

Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation
Bone Marrow Transplantation, 2005
The evaluation of amifostine for mucosal protection in patients with advanced loco-regional Squamous Cell Carcinomas of the Head and Neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily Radiotherapy (RT)
Seminars in Oncology, 2004
Randomized trials of amifostine and radiotherapy: Effect on survival?
Seminars in Oncology, 2004
Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis
International Journal of Radiation Oncology*Biology*Physics, 2004
Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study
Bone Marrow Transplantation, 2003
Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non–Small-Cell Lung Cancer
Journal of Clinical Oncology, 2003
Rationale for a phase III study of erythropoietin as a neurocognitive protectant in patients with lung cancer receiving prophylactic cranial irradiation
Seminars in Oncology, 2002
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non[ndash ]small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings
Seminars in Oncology, 2002
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma
Seminars in Oncology, 2002
A Pilot Study on Feasibility and Efficacy of Amifostine Preceding High-dose Melphalan with Autologous Stem Cell Support in Myeloma Patients
Leukemia & Lymphoma, 2002